• Home
  • About Us
  • Science
    • ImmunoBody®
    • Moditope®
    • Glymab®
    • Publications
  • Pipeline
  • News
  • Investors
    • Share Info
    • Financial Info
    • Documents & Presentations
    • Corporate Governance
  • Contact Us
    • Find a trial
    • Become an Investigator

Interim Results and Business Update

by chantal | Jan 29, 2026 | Latest News, Regulatory News

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

SCOPE Phase 2 Trial Data Update, ESMO December 2025

by chantal | Dec 11, 2025 | Immunobody, iSCIB1+, SCIB1, Vaccines

SCOPE Study Poster, ESMO Immuno-Oncology Congress December 2025

by chantal | Dec 9, 2025 | Immunobody, iSCIB1+, SCIB1

Heather Shaw, Poulam Patel, Miranda Payne, Satish Kumar, Sarah Danson, Martin Highley, Clare Barlow, Kellati Prasad, Ioannis Karydis, Maria Marples, Kate Young, Pippa Corrie, Robert Miller, Georgia Goodhew, Samantha Paston, Gaelle Cane, Joe Chadwick, Lindy Durrant and...

Scancell updated Phase 2 data shows continued improvement in progression free survival with iSCIB1+

by chantal | Dec 9, 2025 | iSCIB1+, Latest News, Regulatory News

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

SCOPE Study Presentation, SITC (Society for Immunotherapy of Cancer) Annual Meeting, November 2025, National Harbor, MD

by chantal | Nov 7, 2025 | Immunobody, iSCIB1+, SCIB1, Vaccines

« Older Entries

Recent Posts

  • iSCIB1+ pivotal trial plans advancing
  • AACR (American Association for Cancer Research) Annual Meeting, April 2026, San Diego, California
  • Scancell Receives FDA Fast Track Designation for iSCIB1+
  • Scancell announces CFO Transition
  • Edison Report – Redesigning immunity: The next frontier in immuno-oncology

Recent Comments

No comments to show.

Scancell is focused on developing novel immunotherapies for the treatment of cancer and was founded in 1996 based on research led by Professor Lindy Durrant at the University of Nottingham in the UK.

  • Follow
  • Follow

About Us
Leadership Team
Science
Our Pipeline
News
Contact Us
Find a Trial
Become an Investigator

ACTIVE IMMUNOTHERAPY

ImmunoBody®
Moditope®

ANTIBODIES

GlyMab®
AvidiMab®

Investors
Company Profile
Advisors
Corporate Governance
Documents & Presentations
Share Information
Financial Information

Copyright © 2026 Scancell | Website Designed & Developed by Identity Creative | Privacy & Cookie Policy